{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:32:49Z","timestamp":1788021169185,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13256-016-1143-9","type":"journal-article","created":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T06:50:53Z","timestamp":1482216653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-6962","authenticated-orcid":false,"given":"Steve","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranshu","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristhiam Mauricio","family":"Rojas Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoneddy","family":"Dayao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,20]]},"reference":[{"key":"1143_CR1","doi-asserted-by":"crossref","unstructured":"Kim S, Shrivastava M, Anampa J, et al. Unusual case of cholestatic jaundice in a patient with AIDS. BMJ Case Rep. 2013;2013. doi:10.1136\/bcr-2013-200113","DOI":"10.1136\/bcr-2013-200113"},{"key":"1143_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"J Henter","year":"2007","unstructured":"Henter J, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124\u201331.","journal-title":"Pediatr Blood Cancer."},{"issue":"4","key":"1143_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/03009734.2015.1064500","volume":"120","author":"T Karlsson","year":"2015","unstructured":"Karlsson T. Secondary haemophagocytic lymphohistiocytosis: Experience from the Uppsala University Hospital. Ups J Med Sci. 2015;120(4):257\u201362.","journal-title":"Ups J Med Sci"},{"issue":"18","key":"1143_CR4","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/cncr.30084","volume":"122","author":"G Tamamyan","year":"2016","unstructured":"Tamamyan G, Kantarjian H, Ning J, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016;122(18):2857\u201366.","journal-title":"Cancer"},{"issue":"4","key":"1143_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1651-2227.1991.tb11878.x","volume":"80","author":"J Henter","year":"1991","unstructured":"Henter J, Elinder G, S\u00f6der O, et al. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1991;80(4):428\u201335.","journal-title":"Acta Paediatr Scand"},{"key":"1143_CR6","doi-asserted-by":"publisher","first-page":"851392","DOI":"10.1155\/2014\/851392","volume":"2014","author":"S Benmiloud","year":"2014","unstructured":"Benmiloud S, Hbibi M, Chaouki S, et al. Hodgkin\u2019s lymphoma revealed by hemophagocytic lymphohistiocytosis in a child. Case Rep Pediatr. 2014;2014:851392. doi: 10.1155\/2014\/851392 .","journal-title":"Case Rep Pediatr."},{"issue":"4","key":"1143_CR7","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3324\/haematol.2009.019562","volume":"95","author":"V Cetica","year":"2010","unstructured":"Cetica V, Pende D, Griffiths G, et al. Molecular basis of familial hemophagocytic lymphohistiocytosis. Haematologica. 2010;95(4):538\u201341.","journal-title":"Haematologica"},{"issue":"5446","key":"1143_CR8","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1126\/science.286.5446.1957","volume":"286","author":"S Stepp","year":"1999","unstructured":"Stepp S, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957\u20139.","journal-title":"Science"},{"issue":"3","key":"1143_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"M Jordan","year":"2004","unstructured":"Jordan M, Hildeman D, Kappler J, et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735\u201343.","journal-title":"Blood"},{"issue":"11","key":"1143_CR10","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1002\/art.22981","volume":"56","author":"N Fall","year":"2007","unstructured":"Fall N, Barnes M, Thornton S, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007;56(11):3793\u2013804.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1143_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1179\/102453308X316013","volume":"13","author":"J Phillips","year":"2008","unstructured":"Phillips J, Staszewski H, Garrison M. Successful treatment of secondary hemophagocytic lymphohistiocytosis in a patient with disseminated histoplasmosis. Hematology. 2008;13(5):282\u20135.","journal-title":"Hematology"},{"issue":"1","key":"1143_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MPH.0b013e3181f84a52","volume":"33","author":"S Imashuku","year":"2011","unstructured":"Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. J Pediatr Hematol Oncol. 2011;33(1):35\u20139.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"1143_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3201\/eid0606.000608","volume":"6","author":"D Fisman","year":"2000","unstructured":"Fisman D. Hemophagocytic syndromes and infection. Emerg Infect Dis. 2000;6(6):601\u20138.","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"1143_CR14","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/art.24883","volume":"60","author":"A Parodi","year":"2009","unstructured":"Parodi A, Davi S, Pringe A, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009;60(11):3388\u201399.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1143_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.23911","volume":"90","author":"Z Otrock","year":"2015","unstructured":"Otrock Z, Eby C. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90(3):220\u20134.","journal-title":"Am J Hematol"},{"issue":"2","key":"1143_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00431-006-0258-1","volume":"166","author":"G Janka","year":"2007","unstructured":"Janka G. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2007;166(2):95\u2013109.","journal-title":"Eur J Pediatr"},{"key":"1143_CR17","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.amjmed.2014.04.034","volume":"127","author":"S Riviere","year":"2014","unstructured":"Riviere S, Galicier L, Coppo P, et al. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med. 2014;127:1118\u201325.","journal-title":"Am J Med."},{"issue":"4","key":"1143_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.mayocp.2013.12.012","volume":"89","author":"S Parikh","year":"2014","unstructured":"Parikh S, Kapoor P, Letendre L, et al. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484\u201392.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1143_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajcp\/91.1.1","volume":"91","author":"S Staal","year":"1989","unstructured":"Staal S, Ambinder R, Beschorner W, et al. A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin\u2019s disease. Am J Clin Pathol. 1989;91(1):1\u20135.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"1143_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1086\/590152","volume":"47","author":"F Menard","year":"2008","unstructured":"Menard F, Besson C, Rince P, et al. Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. Clin Infect Dis. 2008;47(4):531\u20134.","journal-title":"Clin Infect Dis"},{"issue":"19","key":"1143_CR21","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1182\/blood-2015-01-551622","volume":"125","author":"A Schram","year":"2015","unstructured":"Schram A, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125(19):2908\u201314.","journal-title":"Blood"},{"issue":"9","key":"1143_CR22","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/art.38690","volume":"66","author":"L Fardet","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheum (Munch). 2014;66(9):2613\u201320.","journal-title":"Arthritis Rheum (Munch)"},{"issue":"19","key":"1143_CR23","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood-2015-09-666503","volume":"126","author":"P Rosee","year":"2015","unstructured":"Rosee P. First prospective clinical trial in adult HLH. Blood. 2015;126(19):2169\u201371.","journal-title":"Blood"},{"issue":"2","key":"1143_CR24","first-page":"59","volume":"59","author":"L Filatova","year":"2013","unstructured":"Filatova L, Plotnikova A, Gershanovich M, et al. Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis. Vopr Onkol. 2013;59(2):59\u201365.","journal-title":"Vopr Onkol"},{"issue":"18","key":"1143_CR25","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2012-01-402792","volume":"119","author":"Y Kasamon","year":"2012","unstructured":"Kasamon Y, Jacene H, Gocke C, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012;119(18):4129\u201332.","journal-title":"Blood"},{"issue":"8","key":"1143_CR26","first-page":"364","volume":"67","author":"G Bosman","year":"2009","unstructured":"Bosman G, Langemeijer S, Hebeda K, et al. The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis. Neth J Med. 2009;67(8):364\u20135.","journal-title":"Neth J Med"},{"issue":"4","key":"1143_CR27","first-page":"260","volume":"10","author":"S Khagi","year":"2012","unstructured":"Khagi S, Danilova O, Rauwerdink C. Hemophagocytic syndrome in a patient with human immunodeficiency virus, Epstein-Barr viremia, and newly diagnosed Hodgkin lymphoma. Clin Adv Hematol Oncol. 2012;10(4):260\u20135.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1143_CR28","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00277-014-2114-0","volume":"93","author":"J Labrador","year":"2014","unstructured":"Labrador J, Cabrero-Calvo M, Perez-Lopez E, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin\u2019s lymphoma. Ann Hematol. 2014;93:1745\u201353.","journal-title":"Ann Hematol."},{"issue":"6","key":"1143_CR29","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","volume":"12","author":"W Velasquez","year":"1994","unstructured":"Velasquez W, Mclaughlin P, Tucker S, et al. ESHAP \u2013 an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12(6):1169\u201376.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1143_CR30","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal A, Smith S, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30(18):2183\u20139.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1143_CR31","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","volume":"118","author":"T Fehniger","year":"2011","unstructured":"Fehniger T, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118(19):5119\u201325.","journal-title":"Blood"},{"issue":"4","key":"1143_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"S Ansell","year":"2015","unstructured":"Ansell S, Lesokhin A, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med"},{"issue":"17","key":"1143_CR33","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1002\/cncr.25983","volume":"117","author":"B Lee","year":"2011","unstructured":"Lee B, Gao H, Cohen E, et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011;117(17):3999\u20134008.","journal-title":"Cancer"},{"issue":"13","key":"1143_CR34","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1182\/blood-2016-02-697151","volume":"127","author":"P Ros\u00e9e La","year":"2016","unstructured":"La Ros\u00e9e P. Alleviating the storm: ruxolitinib in HLH. Blood. 2016;127(13):1626\u20137.","journal-title":"Blood"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-016-1143-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-016-1143-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-016-1143-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T02:21:15Z","timestamp":1498357275000},"score":1,"resource":{"primary":{"URL":"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-016-1143-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1186\/s13256-016-1143-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"365"}}